Disease · MONDO_0006502
acute respiratory distress syndrome
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. acute respiratory distress syndrome. Diseases, record MONDO_0006502. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006502
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs184
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| METHYLPREDNISOLONE | CHEMBL650 | Small molecule | Phase 3 | ClinicalTrials.gov | 17 | 17 | 13 | Drugs and targets |
| DEXAMETHASONE | CHEMBL384467 | Small molecule | Phase 3 | ClinicalTrials.gov | 16 | 16 | 12 | Drugs and targets |
| HEPARIN | CHEMBL4650299 | Oligosaccharide | Phase 3 | ClinicalTrials.gov | 10 | 10 | 10 | Drugs and targets |
| SEVOFLURANE | CHEMBL1200694 | Small molecule | Phase 3 | ClinicalTrials.gov | 9 | 9 | 8 | Drugs and targets |
| SODIUM CHLORIDE | CHEMBL1200574 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 5 | Drugs and targets |
| PORACTANT ALFA | CHEMBL1201622 | Phase 3 | ClinicalTrials.gov | 6 | 6 | 4 | Drugs and targets | |
| PROPOFOL | CHEMBL526 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| TOCILIZUMAB | CHEMBL1237022 | Antibody | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| BEVACIZUMAB | CHEMBL1201583 | Antibody | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| HYDROCORTISONE | CHEMBL389621 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 3 | Drugs and targets |
1 to 10 of 184
See all 184 drugsTargets180
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 15 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| GABRA1 | GABA-A receptor; anion channel | 5 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2554 | Drugs and targets |
| GABRA2 | GABA-A receptor; anion channel | 5 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2555 | Drugs and targets |
| GABRA3 | GABA-A receptor; anion channel | 5 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2556 | Drugs and targets |
| GABRA4 | GABA-A receptor; anion channel | 5 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2557 | Drugs and targets |
| GABRA5 | GABA-A receptor; anion channel | 5 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2558 | Drugs and targets |
| GABRA6 | GABA-A receptor; anion channel | 5 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2559 | Drugs and targets |
| GABRB1 | GABA-A receptor; anion channel | 5 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2560 | Drugs and targets |
| GABRB2 | GABA-A receptor; anion channel | 5 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2561 | Drugs and targets |
| GABRB3 | GABA-A receptor; anion channel | 5 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2562 | Drugs and targets |
1 to 10 of 180
See all 180 targetsTrials249
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 14 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02509078 | Reevaluation Of Systemic Early Neuromuscular Blockade | Phase 3 | 1,008 | 2019-08-13 | Acute Respiratory Distress Syndrome | CISATRACURIUM BESYLATE | Its record names the disease | ClinicalTrials.gov |
| NCT00979121 | Statins for Acutely Injured Lungs From Sepsis | Phase 3 | 745 | 2014-10-03 | Sepsis, Acute Lung Injury | ROSUVASTATIN | Its record names the disease | ClinicalTrials.gov |
| NCT04291508 | Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery | Phase 2 | 488 | 2024-09-27 | Acute Respiratory Distress Syndrome, Critical Illness, Respiratory Failure, Sepsis | ACETAMINOPHEN | Its record names the disease | ClinicalTrials.gov |
| NCT04843761 | ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19 | Phase 3 | 473 | 2025-10-24 | Covid19 | AVIPTADIL, REMDESIVIR | Its record names the disease | ClinicalTrials.gov |
| NCT04478071 | Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) | Phase 2 | 448 | 2025-03-26 | Acute Respiratory Distress Syndrome, Coronavirus Infection | VADADUSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT04817332 | STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19 | Phase 3 | 406 | 2023-08-22 | Covid19 | BRENSOCATIB | Its record names the disease | ClinicalTrials.gov |
| NCT02622724 | Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS) | Phase 3 | 301 | 2020-03-30 | Respiratory Distress Syndrome, Adult | INTERFERON BETA-1A | Its record names the disease | ClinicalTrials.gov |
| NCT00434993 | Drug Study of Albuterol to Treat Acute Lung Injury | Phase 2/3 | 282 | 2013-07-15 | Respiratory Distress Syndrome, Adult | ALBUTEROL SULFATE | Its record names the disease | ClinicalTrials.gov |
| NCT04351243 | A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) | Phase 2 | 227 | 2021-12-10 | COVID-19 | GIMSILUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02636868 | The Safety and Efficacy of Lucinactant for Inhalation in Premature Neonates 26 to 32 Weeks Gestational Age | Phase 2 | 221 | 2021-04-23 | Respiratory Distress Syndrome | LUCINACTANT | Open Targets' reading of its record | ClinicalTrials.gov |
1 to 10 of 249
See all 249 trialsComparisons in its trials92
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Early Neuromuscular Blockade (NMB) vs Control: No Routine Early NMB: deaths from any cause | 213 of 501 | 216 of 505 | 1,006 | NCT02509078 | Trial comparisons |
| Early Neuromuscular Blockade (NMB) vs Control: No Routine Early NMB: serious adverse events | 28 of 501 | 21 of 505 | 1,006 | NCT02509078 | Trial comparisons |
| Rosuvastatin vs Placebo: serious adverse events | 34 of 379 | 32 of 366 | 745 | NCT00979121 | Trial comparisons |
| Vadadustat vs Placebo: deaths from any cause | 19 of 221 | 19 of 227 | 448 | NCT04478071 | Trial comparisons |
| Vadadustat vs Placebo: serious adverse events | 61 of 221 | 73 of 227 | 448 | NCT04478071 | Trial comparisons |
Vadadustat vs Placebo: Number of Participants Who Are Classified 8 (Dead), 7 (Hospitalized, on Invasive Mechanical Ventilation or ECMO), or 6 (Hospitalized, on Non-invasive Ventilation or High Flow Oxygen Devices) on the NIAID Ordinal Scale | 43 of 216 | 53 of 223 | 439 | NCT04478071 | Trial comparisons |
| Vadadustat vs Placebo: Number of Participants With a Total Score of 0 on the Modified Sequential Organ Failure Assessment (MSOFA) Scale | 156 of 214 | 157 of 223 | 437 | NCT04478071 | Trial comparisons |
| Brensocatib vs Placebo: Cumulative Incidence of Serious Adverse Events (SAEs) | 40 of 192 | 35 of 214 | 406 | NCT04817332 | Trial comparisons |
| Brensocatib vs Placebo: Discontinuation or Temporary Suspension of Treatment | 13 of 192 | 12 of 214 | 406 | NCT04817332 | Trial comparisons |
| Brensocatib vs Placebo: deaths from any cause | 29 of 192 | 23 of 214 | 406 | NCT04817332 | Trial comparisons |
1 to 10 of 92
See all 92 comparisons in its trialsPapers from its trials218
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006502
GET https://conductscience.org/api/diseases/v1/MONDO_0006502/drugs?page=2